



**Contact:**

David Waldman or Natalya Rudman  
Crescendo Communications, LLC  
Email: [mlss@crescendo-ir.com](mailto:mlss@crescendo-ir.com)  
Tel: 212-671-1020

**Milestone Scientific Appoints Senior Healthcare Industry Executive  
Steven F. Robins as Marketing Consultant**

**LIVINGSTON, NJ, July 30, 2014 -- Milestone Scientific Inc. (OTCQB: MLSS)**, a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced the appointment of Steven F. Robins to the position of Marketing Consultant.

Prior to joining Milestone, Mr. Robins was Chief Marketing Officer of the Vision Care division of BAUSCH + LOMB where he was responsible for all marketing for the \$1.3 billion global Vision Care business unit. He also served as President of Vision Care North America, where he oversaw commercial operations for the North American market. Prior to that, he also held senior marketing and operational roles with Johnson & Johnson and Pfizer where he was responsible for the business performance for a number of leading consumer brands.

Leonard Osser, Chief Executive Officer of Milestone Scientific, commented, "We are impressed with Steven's track record as well as his vision for our marketing efforts. His expertise with positioning, branding and lead generation coupled with his business-to-business and consumer marketing experience are perfectly suited to Milestone's needs. He brings an impressive background overseeing marketing and operations for billion dollar divisions of Fortune 500 healthcare and consumer product companies. We look forward to his valuable contributions to our growth as we accelerate our domestic and international sales and marketing initiatives."

Mr. Robins commented, "I am pleased to join Milestone Scientific at this important inflection point. The STA Wand has a proven track record and has been well received by both consumers and dentists alike. I look forward to helping drive awareness of the clinical benefits, as well as the commercial benefits for dentists. Additionally, Milestone's platform technology has broad implications across a number of medical fields, including the epidural and intra-articular instruments. Each of these instruments represents a sizable market in its own right and this technology has the potential to become the standard of care, as medical practitioners become aware of the safety and medical benefits. I look forward to working closely with the senior management team to realize the full potential of Milestone's intellectual property portfolio."

## **About Milestone Scientific Inc.**

Milestone Scientific Inc. is a leading medical research and development company that designs and patents innovative injection technology. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website: [www.milestonescientific.com](http://www.milestonescientific.com).

### **Safe Harbor Statement**

*This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2013. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.*

###